相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical outcome measures in SPMS trials: An analysis of the IMPACT and ASCEND original trial data sets
Marcus W. Koch et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Domperidone-induced elevation of serum prolactin levels and immune response in multiple sclerosis
Marcus W. Koch et al.
JOURNAL OF NEUROIMMUNOLOGY (2019)
Progressive multiple sclerosis: from pathophysiology to therapeutic strategies
Simon Faissner et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Ludwig Kappos et al.
LANCET (2018)
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Raja Kapoor et al.
LANCET NEUROLOGY (2018)
The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis
Peter Feys et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis
Robert W. Motl et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Targets of therapy in progressive MS
Hans Lassmann
MULTIPLE SCLEROSIS JOURNAL (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Systematic screening of generic drugs for progressive multiple sclerosis identifies clomipramine as a promising therapeutic
Simon Faissner et al.
NATURE COMMUNICATIONS (2017)
The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis
Peter Feys et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis
Robert W. Motl et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Targets of therapy in progressive MS
Hans Lassmann
MULTIPLE SCLEROSIS JOURNAL (2017)
Progressive multiple sclerosis 1 Pathological mechanisms in progressive multiple sclerosis
Don H. Mahad et al.
LANCET NEUROLOGY (2015)
The promise of futility trials in neurological diseases
Marcus W. Koch et al.
NATURE REVIEWS NEUROLOGY (2015)
Drug Repurposing: A Systematic Approach to Evaluate Candidate Oral Neuroprotective Interventions for Secondary Progressive Multiple Sclerosis
Hanna M. Vesterinen et al.
PLOS ONE (2015)
Screening for Inhibitors of Microglia to Reduce Neuroinflammation
Shazia Samanani et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2013)
Treatment trials in progressive MS-current challenges and future directions
Marcus W. Koch et al.
NATURE REVIEWS NEUROLOGY (2013)
Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results
J. D. Bowen et al.
BONE MARROW TRANSPLANTATION (2012)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
Prolactin increases SMN expression and survival in a mouse model of severe spinal muscular atrophy via the STAT5 pathway
Faraz Farooq et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
White matter plasticity and enhanced remyelination in the maternal CNS
Christopher Gregg et al.
JOURNAL OF NEUROSCIENCE (2007)
Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis -: reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations
Florian Then Bergh et al.
BMC NEUROLOGY (2006)
Benefit of interferon β-1a on MSFC progression in secondary progressive MS
JA Cohen et al.
NEUROLOGY (2002)
分享论文
